Surgeons Will Test LUM Imaging System to Better Detect Ovarian, Other Cancer Cells

Surgeons Will Test LUM Imaging System to Better Detect Ovarian, Other Cancer Cells
Lumicell is assessing its LUM Imaging System as a means to help surgeons better detect cancer cells that spread into the peritoneum — the membrane lining the abdominal cavity and covering the abdominal organs – during surgery, the company announced. The clinical trial (NCT03834272) — which is recruiting participants at  Massachusetts General Hospital in Boston — is for those with primary ovarian cancer, appendix cancer, gastrointestinal cancer, and mesothelioma  whose cancer has spread into the peritoneum and are receiving their first surgery. In one-third of cancer surgeries, surgeons fail to identify and remove the tumors completely, which may worsen a patient's outcome significantly and require additional surgeries. Lumicell is working to empower surgeons to better detect cancer cells, ensuring that all traces of the tumor are removed in a single surgery. The company uses a dye, called LUM015, that becomes fluorescent in the presence of cathepsins, which are a group of proteins largely produced by cancer cells. This illuminates the cancer cells, enabling surgeons to see and remove cancer cells. The system comes with a handheld device to detect the illuminated cancer cells. The LUM Imaging System has been tested with success during breast cancer surgery. In a study led by Barbara Smith, MD, PhD, director of the Breast Program at Massachusetts General Hospital, the imaging system effectively identified resid
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *